Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...

Patients in the treatment arms received 1 mg, 2.5 mg, 5 mg or 10 mg doses. After 52 weeks of treatment, patients taking the ...

Learn about HMGB1's crucial role in liver diseases, its pathways and therapeutic potential that can treat liver diseases.

Carisma Therapeutics Inc. (CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at the ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

Liver steatosis is more prevalent than liver fibrosis in people with HIV, with significant risk factors including age, hypertension, and diabetes. Liver fibrosis prevalence is low, with integrase ...

Scientists there say they've successfully reversed liver fibrosis in mice ... that too often leaves patients and doctors with few treatment options," he said in a Cedars Sinai news release.